Long-term safety study of litifilimab for skin lupus
Part of Skin clinical trials.
This study is a long-term follow-up for people who already completed a 52-week study of the study drug litifilimab for active skin lupus. It will check the safety of continued treatment and see if it keeps helping symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have completed the full 52-week parent study (all treatments and study visits).
- You should not have stopped treatment or dropped out early from the parent study.
- You must not have developed any new medical conditions that make this study unsafe for you.
- You must be able to understand the study and give your permission (consent) to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
This study tests whether a medicine called belimumab (Benlysta) works better for people diagnosed with lupus in the last 2 years. It aims to slow down the disease before it causes lasting organ damage.
This study follows people with systemic lupus erythematosus (SLE) who already took part in an earlier, 1-year placebo-controlled trial. It looks at the long-term safety of litifilimab and whether it helps improve lupus symptoms over time.
This trial lets people who completed a prior anifrolumab study and saw benefit continue receiving the drug. It monitors long-term safety and effectiveness.
This study tests the long-term safety and effectiveness of the drug leniolisib for people with certain immune system disorders. It is for people who have already been in a previous study of this drug and may benefit from continuing treatment.
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
Hear when a new Subacute Cutaneous Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.